Roles
- Assistant Professor of Clinical Medicine
-
Biography
Dr. Carpintero is an Assistant Professor of Clinical Medicine in the division of rheumatology. She is a clinical investigator with a focus on systemic autoimmune diseases especially Systemic Lupus Erythematosus (SLE). She has participated as principal investigator in multiple clinical trials and her research focus is on identifying information that may ultimately be useful finding better treatment options and to be able to improve the lives of patients with systemic autoimmune diseases in particularly with SLE. In addition to caring for patients in the clinic, she enjoys medical education and the opportunity to teach medical students, residents, and fellows; she currently serves as Associate Program Director for the rheumatology fellowship, Director for the rheumatology pathway for the Internal Medicine residency program and Coordinator/faculty mentor for the Tozman Scholar program. -
Education & Training
Education
Licensures and Certifications
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 8 clinical trials.
-
The study will be conducted to assess the efficacy, safety and tolerability of Dapirolizumab Pegol (DPZ) in study participants with active SLE despite standard therapy. This study is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 study in study participants with moderately to severely active SLE who are receiving stable SOC medication (ie, antimalarials, corticosteroids, and/or immunosuppressants)in line with local and international guidances at screening visit. It will primarily investigate the improvement of SLE disease activity in study participants treated with DZP as add-on to nonbiological SOC treatment over 48 weeks.
- Principal Investigator: Maria Carpintero
- Study Phase: Phase III
- Enrollment Status: Closed
-
The primary objective of the study is to demonstrate superiority ofdeucravacitinib compared to PBO in treatment of participants with SLE. with respect to SRI(4). Secondary objective to evaluate the efficacy of deucravacitinib compared to PBO on additional measures of clinical disease activity.
- Principal Investigator: Maria Carpintero
- Study Phase: TBD
- Enrollment Status: Not Accepting
-
The primary objective of this study is to demonstrate superiority of Ianalumab , compared to Placebo in achieving stable complete renal response at week 72.
- Principal Investigator: Maria Carpintero
- Study Phase: TBD
- Enrollment Status: Not Accepting
-
This is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study designed to evaluate the efficacy and safety of BIIB059 in adult participants with active SLE, including joint and/or skin manifestations, who are receiving background nonbiologic lupus SOC therapy.The study includes a screening period of up to 4 weeks; adouble-blind, placebo-controlled treatment period of 52 weeks;and an SFU period (off-treatment) of 24 weeks (for early studytreatment terminators or the 52-week treatment periodcompleters who do not enter the LTE study). During the screening period, participants who sign the ICF will undergo all the screening procedures to determine their eligibility to participate in the study. To enroll in the study, participants are required to be currently treated with a stable background nonbiologic lupus SOC therapy and to continue lupus SOC therapy.
- Principal Investigator: Maria Carpintero
- Study Phase: Phase III
- Enrollment Status: Closed
-
The primary objective of this study is to evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state. Secondary objective is to evaluate the effect of dazodalibep on measures of patient-reported outcomes (PROs) in participants with SS.
- Principal Investigator: Maria Carpintero
- Study Phase: TBD
- Enrollment Status: Closed
-
The objective is to evaluate the safety and efficacy of upadacitinib compared with placebo for the treatment of signs and symptoms of SLE for 52 weeks in adults with moderately to severely active SLE
- Principal Investigator: Maria Carpintero
- Study Phase: TBD
- Enrollment Status: Not Accepting
-
The primary objective of this study is to demonstrate superiority of subcutaneous ianalumab 300 mg monthly, compared to placebo, inachieving Systemic Lupus Erythematosus Responder Index (SRI-4) at Week 60.
- Principal Investigator: Maria Carpintero
- Study Phase: TBD
- Enrollment Status: Closed
-
The primary objective of this study is to evaluate the effect of dazodalibep on systemic manifestations of SS in participants with moderate-to-severe systemic disease activity.
- Principal Investigator: Maria Carpintero
- Study Phase: Phase III
- Enrollment Status: Closed
